ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TBV Tiens Biotech Grp. (Usa) Common Stock

0.00
0.00 (0.00%)
After Hours
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tiens Biotech Grp. (Usa) Common Stock AMEX:TBV AMEX Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

- Current report filing (8-K)

17/08/2010 7:38pm

Edgar (US Regulatory)



 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  August 13, 2010
 
TIENS BIOTECH GROUP (USA), INC.
 
(Exact name of registrant as specified in its charter)
 
         
Delaware  
 
001-32477  
 
75-2926439
(State or other jurisdiction  
 
(Commission File Number)  
 
(I.R.S. Employer  
of incorporation)  
     
Identification Number)  
 
No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700
 
(Address of principal executive offices)
 
Registrant's telephone number, including area code: 86 22 - 8213- 7335
 
Not applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On August 13, 2010, the Board of Directors of Tiens Biotech Group (USA), Inc. (the “Company”) appointed Jinyuan Li, Chairman, Chief Executive Officer and President of the Company, as Acting Chief Financial Officer of the Company to fill the vacancy created by the resignation of Manbo He, the Company’s former Chief Financial Officer, who resigned on June 17, 2010.
 
Other information required by this Item regarding Mr. Li is omitted, as it has been previously reported.
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
TIENS BIOTECH GROUP (USA), INC.
   
    
 
Date:  August 17, 2010
By:
/s/ Jinyuan Li
   
Name:   Jinyuan Li
   
Title:    Chairman, Chief Executive
Officer and President

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3

1 Year Tiens Biotech GR Usa Chart

1 Year Tiens Biotech GR Usa Chart

1 Month Tiens Biotech GR Usa Chart

1 Month Tiens Biotech GR Usa Chart

Your Recent History

Delayed Upgrade Clock